Spain holds unknown keys to Baxter lessons?
This article was originally published in Clinica
Executive Summary
The Spanish health ministry's investigation into the deaths of dialysis patients in three hospitals in August has so far resulted in a report that appears to corroborate Baxter's admission of "probable" guilt (see this issue, pages 1-2). However, the lessons to be learnt may be found in what has not yet been reported, but which remains concealed in the criminal investigation underway in the Valencia region, subject to which evidence the national ministry's report is "provisional".
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.